共 205 条
[1]
Collaboration ERF(2013)Standards of medical care in diabetes–2013 Diabetes Care 36 S11-S66
[2]
Sarwar N(2010)Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet 375 2215-2222
[3]
Gao P(2009)Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes J Am Soc Nephrol 20 1813-1821
[4]
Seshasai SR(2011)Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations Ann Intern Med 154 602-613
[5]
Gobin R(2013)Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial Diab Vasc Dis Res 10 289-301
[6]
Kaptoge S(1991)Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement Am Heart J 121 1244-1263
[7]
Di Angelantonio E(2013)Incorporating lag time to benefit into prevention decisions for older adults JAMA 310 2609-2610
[8]
Ingrlsson E(2011)Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes Endocr Rev 32 515-531
[9]
Lawlor DA(2012)Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors Diabetes Obes Metab 14 83-90
[10]
Selvin E(2013)Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial Diabetes Care 36 3396-3404